Insider Buying: OPKO Health (NASDAQ:OPK) Director Purchases $11,400.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) Director John Paganelli acquired 10,000 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was acquired at an average price of $1.14 per share, with a total value of $11,400.00. Following the completion of the transaction, the director directly owned 394,340 shares of the company’s stock, valued at approximately $449,547.60. This represents a 2.60% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

OPKO Health Stock Performance

Shares of NASDAQ:OPK traded down $0.05 during midday trading on Friday, reaching $1.12. 4,521,528 shares of the company’s stock traded hands, compared to its average volume of 2,344,678. OPKO Health, Inc. has a 1 year low of $1.10 and a 1 year high of $1.83. The company has a current ratio of 3.97, a quick ratio of 3.52 and a debt-to-equity ratio of 0.26. The company has a fifty day simple moving average of $1.23 and a two-hundred day simple moving average of $1.34.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. The business had revenue of $148.50 million for the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative net margin of 37.19% and a negative return on equity of 17.42%. The company’s revenue was down 19.1% compared to the same quarter last year. During the same period last year, the firm posted $0.01 earnings per share. As a group, research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analysts Set New Price Targets

OPK has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, January 22nd. Wall Street Zen lowered OPKO Health from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Barrington Research lowered their price objective on OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Finally, JPMorgan Chase & Co. initiated coverage on OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.03.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently bought and sold shares of the company. Caprock Group LLC purchased a new position in OPKO Health during the 3rd quarter valued at about $26,000. Zacks Investment Management purchased a new stake in OPKO Health during the fourth quarter worth about $27,000. StoneX Group Inc. acquired a new stake in shares of OPKO Health during the fourth quarter worth about $27,000. Swiss Life Asset Management Ltd purchased a new position in shares of OPKO Health in the third quarter valued at approximately $30,000. Finally, Savant Capital LLC purchased a new position in shares of OPKO Health in the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.